+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Active Pharmaceutical Ingredients CDMO Market by Service Type, Molecule Type, Production Scale, Therapeutic Area, Manufacturing Technology - Global Forecast to 2030- Product Image
Active Pharmaceutical Ingredients CDMO Market by Service Type, Molecule Type, Production Scale, Therapeutic Area, Manufacturing Technology - Global Forecast to 2030- Product Image
Sale

Active Pharmaceutical Ingredients CDMO Market by Service Type, Molecule Type, Production Scale, Therapeutic Area, Manufacturing Technology - Global Forecast to 2030

  • PDF Icon

    Report

  • 181 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 6015020
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The active pharmaceutical ingredients (API) CDMO market is transitioning rapidly as pharmaceutical and biotechnology companies look for new ways to accelerate development, strengthen supply chains, and access advanced manufacturing and process technologies. Strategic partners are assuming more critical roles in driving success and enabling pharmaceutical innovation within a complex global framework.

Market Snapshot: Active Pharmaceutical Ingredients CDMO Market

The Active Pharmaceutical Ingredients CDMO Market grew from USD 126.42 billion in 2024 to USD 140.01 billion in 2025, with a projected CAGR of 10.45%. The market is forecast to reach USD 229.63 billion by 2030. This robust upward trajectory underlines the increasing demand for specialized CDMO services worldwide, propelled by advances in scientific research, evolving regulatory landscapes, and the need for versatile manufacturing partners. Growth continues across therapeutics, modalities, and regions as industry leaders seek solutions that de-risk supply chains, shorten time-to-market, and capitalize on new technologies.

Scope & Segmentation

This report delivers comprehensive coverage of the API CDMO industry across all major segments, enabling senior decision-makers to benchmark and strategize with clarity.

  • Service Type: Analytical services such as method development and QC testing; clinical manufacturing across all clinical phases; commercial manufacturing for both small and large batches; end-to-end process development from early to late-stage.
  • Molecule Type: Cell therapies (allogenic, autologous), gene therapies (AAV, lentiviral), oligonucleotides (ASOs, mRNA, siRNA), peptides (cyclic, linear), proteins (enzymes, monoclonal antibodies, recombinant proteins), small molecules (APIs and intermediates).
  • Production Scale: Clinical scale across Phases I–III; commercial scale for bulk API synthesis and fill finish operations.
  • Therapeutic Area: Cardiovascular, central nervous system, infectious diseases, oncology, plus other tailored therapeutic needs.
  • Manufacturing Technology: Biocatalysis (enzymatic, whole cell), fermentation (mammalian cell, microbial), advanced synthetic chemistry.
  • Geographic Coverage: Americas (including United States, Canada, Mexico, Brazil, Argentina), Europe, Middle East & Africa (including United Kingdom, Germany, France, major EU and EMEA markets), Asia-Pacific (covering China, India, Japan, Australia, and key Southeast Asian countries).
  • Company Profiles: Leading organizations such as Lonza Group Ltd, Thermo Fisher Scientific Inc, Catalent Inc, Evonik Industries AG, WuXi AppTec, Siegfried Holding AG, Divi’s Laboratories, Jubilant Life Sciences Ltd, Piramal Enterprises, and Granules India Ltd.

Key Takeaways for Senior Decision-Makers

  • Major pharmaceutical and biotech companies are relying more on CDMOs for end-to-end solutions, not just manufacturing, integrating them into their R&D and commercialization strategies.
  • Demand is expanding for platforms supporting advanced modalities, such as cell and gene therapies, as well as innovative oligonucleotides, reflecting shifts toward personalized medicine.
  • Flexible manufacturing solutions and modular facility design are essential to maintain responsiveness amid uncertain global demand and evolving regulatory requirements.
  • Digital integration and real-time analytics are shaping competitive differentiation, driving both process efficiencies and enhanced client transparency.
  • Strategic alliances and co-innovation between biotech firms and large CDMOs are accelerating development cycles, while also spreading risk and aligning commercial goals.
  • Expanding regional footprints—especially in Asia-Pacific, North America, and EMEA—ensure access to scalable, compliant manufacturing near key markets.

Tariff Impact: Navigating New US Measures

The introduction of new US tariffs in 2025 has flipped the dynamics for API supply chains, prompting CDMOs to adapt sourcing networks and rebalance production economics. While these tariffs aim to bolster domestic capabilities, they have introduced new cost streams necessitating dual-sourcing strategies and renegotiation of supplier relationships. The industry is both investing in advanced US-based facilities and leveraging government incentives in response, building a more resilient API ecosystem over time.

Research Methodology & Data Sources

The analysis uses comprehensive primary research—structured executive interviews across major pharmaceutical, CDMO, and regulatory organizations—and a robust secondary research review, covering published literature, industry reports, patents, and global regulatory filings. Data triangulation and multi-stage expert validation underpin all trend assessments and market forecasts.

Why This Report Matters

  • Guides strategic investment decisions by clarifying opportunities for growth and risk mitigation across segments and regions.
  • Enables benchmarking against best practices, emerging technologies, and new partnership models to support pipeline evolution and market expansion.
  • Equips leaders to develop agile supply chain, regulatory, and production strategies suited to today’s rapidly evolving pharmaceutical environment.

Conclusion

Senior leaders looking to excel in the API CDMO market must balance technological innovation, flexible capacity, and robust risk management strategies. The future will favor those who align operational agility with scientific expertise, enabling scalable and reliable pharmaceutical partnerships.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Active Pharmaceutical Ingredients CDMO Market, by Service Type
8.1. Introduction
8.2. Analytical Services
8.2.1. Method Development
8.2.2. QC Testing
8.3. Clinical Manufacturing
8.3.1. Phase I
8.3.2. Phase II
8.3.3. Phase III
8.4. Commercial Manufacturing
8.4.1. Large Batch Production
8.4.2. Small Batch Production
8.5. Process Development
8.5.1. Early Stage Development
8.5.2. Late Stage Development
9. Active Pharmaceutical Ingredients CDMO Market, by Molecule Type
9.1. Introduction
9.2. Cell Therapies
9.2.1. Allogenic
9.2.2. Autologous
9.3. Gene Therapies
9.3.1. AAV
9.3.2. Lentiviral
9.4. Oligonucleotides
9.4.1. ASOs
9.4.2. mRNA
9.4.3. siRNA
9.5. Peptides
9.5.1. Cyclic Peptides
9.5.2. Linear Peptides
9.6. Proteins
9.6.1. Enzymes
9.6.2. Monoclonal Antibodies
9.6.3. Recombinant Proteins
9.7. Small Molecules
9.7.1. APIs
9.7.2. Intermediates
10. Active Pharmaceutical Ingredients CDMO Market, by Production Scale
10.1. Introduction
10.2. Clinical Scale
10.2.1. Phase I Scale
10.2.2. Phase II Scale
10.2.3. Phase III Scale
10.3. Commercial Scale
10.3.1. Bulk API
10.3.2. Fill Finish
11. Active Pharmaceutical Ingredients CDMO Market, by Therapeutic Area
11.1. Introduction
11.2. Cardiovascular
11.3. Central Nervous System
11.4. Infectious Diseases
11.5. Oncology
12. Active Pharmaceutical Ingredients CDMO Market, by Manufacturing Technology
12.1. Introduction
12.2. Biocatalysis
12.2.1. Enzymatic
12.2.2. Whole Cell
12.3. Fermentation
12.3.1. Mammalian Cell Fermentation
12.3.2. Microbial Fermentation
12.4. Synthetic Chemistry
13. Americas Active Pharmaceutical Ingredients CDMO Market
13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. Argentina
14. Europe, Middle East & Africa Active Pharmaceutical Ingredients CDMO Market
14.1. Introduction
14.2. United Kingdom
14.3. Germany
14.4. France
14.5. Russia
14.6. Italy
14.7. Spain
14.8. United Arab Emirates
14.9. Saudi Arabia
14.10. South Africa
14.11. Denmark
14.12. Netherlands
14.13. Qatar
14.14. Finland
14.15. Sweden
14.16. Nigeria
14.17. Egypt
14.18. Turkey
14.19. Israel
14.20. Norway
14.21. Poland
14.22. Switzerland
15. Asia-Pacific Active Pharmaceutical Ingredients CDMO Market
15.1. Introduction
15.2. China
15.3. India
15.4. Japan
15.5. Australia
15.6. South Korea
15.7. Indonesia
15.8. Thailand
15.9. Philippines
15.10. Malaysia
15.11. Singapore
15.12. Vietnam
15.13. Taiwan
16. Competitive Landscape
16.1. Market Share Analysis, 2024
16.2. FPNV Positioning Matrix, 2024
16.3. Competitive Analysis
16.3.1. Lonza Group Ltd
16.3.2. Thermo Fisher Scientific Inc
16.3.3. Catalent Inc
16.3.4. Evonik Industries AG
16.3.5. WuXi AppTec Co., Ltd
16.3.6. Siegfried Holding AG
16.3.7. Divi’s Laboratories Ltd
16.3.8. Jubilant Life Sciences Ltd
16.3.9. Piramal Enterprises Ltd
16.3.10. Granules India Ltd
17. ResearchAI
18. ResearchStatistics
19. ResearchContacts
20. ResearchArticles
21. Appendix
List of Figures
FIGURE 1. ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET MULTI-CURRENCY
FIGURE 2. ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET MULTI-LANGUAGE
FIGURE 3. ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY SERVICE TYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY SERVICE TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY MOLECULE TYPE, 2024 VS 2030 (%)
FIGURE 10. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY MOLECULE TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY PRODUCTION SCALE, 2024 VS 2030 (%)
FIGURE 12. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY PRODUCTION SCALE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY THERAPEUTIC AREA, 2024 VS 2030 (%)
FIGURE 14. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY THERAPEUTIC AREA, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY MANUFACTURING TECHNOLOGY, 2024 VS 2030 (%)
FIGURE 16. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY MANUFACTURING TECHNOLOGY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. AMERICAS ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. AMERICAS ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. UNITED STATES ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 20. UNITED STATES ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 26. ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY ANALYTICAL SERVICES, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY METHOD DEVELOPMENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY QC TESTING, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY ANALYTICAL SERVICES, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY CLINICAL MANUFACTURING, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY PHASE I, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY PHASE II, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY PHASE III, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY CLINICAL MANUFACTURING, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY COMMERCIAL MANUFACTURING, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY LARGE BATCH PRODUCTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY SMALL BATCH PRODUCTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY COMMERCIAL MANUFACTURING, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY PROCESS DEVELOPMENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY EARLY STAGE DEVELOPMENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY LATE STAGE DEVELOPMENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY CELL THERAPIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY ALLOGENIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY AUTOLOGOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY CELL THERAPIES, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY GENE THERAPIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY AAV, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY LENTIVIRAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY GENE THERAPIES, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY OLIGONUCLEOTIDES, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY ASOS, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY MRNA, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY SIRNA, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY OLIGONUCLEOTIDES, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY PEPTIDES, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY CYCLIC PEPTIDES, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY LINEAR PEPTIDES, BY REGION, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY PEPTIDES, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY PROTEINS, BY REGION, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY ENZYMES, BY REGION, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY RECOMBINANT PROTEINS, BY REGION, 2018-2030 (USD MILLION)
TABLE 46. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY PROTEINS, 2018-2030 (USD MILLION)
TABLE 47. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY SMALL MOLECULES, BY REGION, 2018-2030 (USD MILLION)
TABLE 48. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY APIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 49. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY INTERMEDIATES, BY REGION, 2018-2030 (USD MILLION)
TABLE 50. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY SMALL MOLECULES, 2018-2030 (USD MILLION)
TABLE 51. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY PRODUCTION SCALE, 2018-2030 (USD MILLION)
TABLE 52. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY CLINICAL SCALE, BY REGION, 2018-2030 (USD MILLION)
TABLE 53. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY PHASE I SCALE, BY REGION, 2018-2030 (USD MILLION)
TABLE 54. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY PHASE II SCALE, BY REGION, 2018-2030 (USD MILLION)
TABLE 55. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY PHASE III SCALE, BY REGION, 2018-2030 (USD MILLION)
TABLE 56. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY CLINICAL SCALE, 2018-2030 (USD MILLION)
TABLE 57. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY COMMERCIAL SCALE, BY REGION, 2018-2030 (USD MILLION)
TABLE 58. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY BULK API, BY REGION, 2018-2030 (USD MILLION)
TABLE 59. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY FILL FINISH, BY REGION, 2018-2030 (USD MILLION)
TABLE 60. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY COMMERCIAL SCALE, 2018-2030 (USD MILLION)
TABLE 61. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 62. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY CARDIOVASCULAR, BY REGION, 2018-2030 (USD MILLION)
TABLE 63. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY CENTRAL NERVOUS SYSTEM, BY REGION, 2018-2030 (USD MILLION)
TABLE 64. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2030 (USD MILLION)
TABLE 65. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
TABLE 66. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY MANUFACTURING TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 67. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY BIOCATALYSIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 68. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY ENZYMATIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 69. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY WHOLE CELL, BY REGION, 2018-2030 (USD MILLION)
TABLE 70. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY BIOCATALYSIS, 2018-2030 (USD MILLION)
TABLE 71. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY FERMENTATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 72. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY MAMMALIAN CELL FERMENTATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 73. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY MICROBIAL FERMENTATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 74. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY FERMENTATION, 2018-2030 (USD MILLION)
TABLE 75. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY SYNTHETIC CHEMISTRY, BY REGION, 2018-2030 (USD MILLION)
TABLE 76. AMERICAS ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 77. AMERICAS ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY ANALYTICAL SERVICES, 2018-2030 (USD MILLION)
TABLE 78. AMERICAS ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY CLINICAL MANUFACTURING, 2018-2030 (USD MILLION)
TABLE 79. AMERICAS ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY COMMERCIAL MANUFACTURING, 2018-2030 (USD MILLION)
TABLE 80. AMERICAS ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 81. AMERICAS ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 82. AMERICAS ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY CELL THERAPIES, 2018-2030 (USD MILLION)
TABLE 83. AMERICAS ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY GENE THERAPIES, 2018-2030 (USD MILLION)
TABLE 84. AMERICAS ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY OLIGONUCLEOTIDES, 2018-2030 (USD MILLION)
TABLE 85. AMERICAS ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY PEPTIDES, 2018-2030 (USD MILLION)
TABLE 86. AMERICAS ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY PROTEINS, 2018-2030 (USD MILLION)
TABLE 87. AMERICAS ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY SMALL MOLECULES, 2018-2030 (USD MILLION)
TABLE 88. AMERICAS ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY PRODUCTION SCALE, 2018-2030 (USD MILLION)
TABLE 89. AMERICAS ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY CLINICAL SCALE, 2018-2030 (USD MILLION)
TABLE 90. AMERICAS ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY COMMERCIAL SCALE, 2018-2030 (USD MILLION)
TABLE 91. AMERICAS ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 92. AMERICAS ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY MANUFACTURING TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 93. AMERICAS ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY BIOCATALYSIS, 2018-2030 (USD MILLION)
TABLE 94. AMERICAS ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY FERMENTATION, 2018-2030 (USD MILLION)
TABLE 95. AMERICAS ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 96. UNITED STATES ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 97. UNITED STATES ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY ANALYTICAL SERVICES, 2018-2030 (USD MILLION)
TABLE 98. UNITED STATES ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY CLINICAL MANUFACTURING, 2018-2030 (USD MILLION)
TABLE 99. UNITED STATES ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY COMMERCIAL MANUFACTURING, 2018-2030 (USD MILLION)
TABLE 100. UNITED STATES ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 101. UNITED STATES ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 102. UNITED STATES ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY CELL THERAPIES, 2018-2030 (USD MILLION)
TABLE 103. UNITED STATES ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY GENE THERAPIES, 2018-2030 (USD MILLION)
TABLE 104. UNITED STATES ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY OLIGONUCLEOTIDES, 2018-2030 (USD MILLION)
TABLE 105. UNITED STATES ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY PEPTIDES, 2018-2030 (USD MILLION)
TABLE 106. UNITED STATES ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY PROTEINS, 2018-2030 (USD MILLION)
TABLE 107. UNITED STATES ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY SMALL MOLECULES, 2018-2030 (USD MILLION)
TABLE 108. UNITED STATES ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY PRODUCTION SCALE, 2018-2030 (USD MILLION)
TABLE 109. UNITED STATES ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY CLINICAL SCALE, 2018-2030 (USD MILLION)
TABLE 110. UNITED STATES ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY COMMERCIAL SCALE, 2018-2030 (USD MILLION)
TABLE 111. UNITED STATES ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 112. UNITED STATES ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY MANUFACTURING TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 113. UNITED STATES ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY BIOCATALYSIS, 2018-2030 (USD MILLION)
TABLE 114. UNITED STATES ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY FERMENTATION, 2018-2030 (USD MILLION)
TABLE 115. UNITED STATES ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 116. CANADA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 117. CANADA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY ANALYTICAL SERVICES, 2018-2030 (USD MILLION)
TABLE 118. CANADA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY CLINICAL MANUFACTURING, 2018-2030 (USD MILLION)
TABLE 119. CANADA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY COMMERCIAL MANUFACTURING, 2018-2030 (USD MILLION)
TABLE 120. CANADA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 121. CANADA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 122. CANADA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY CELL THERAPIES, 2018-2030 (USD MILLION)
TABLE 123. CANADA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY GENE THERAPIES, 2018-2030 (USD MILLION)
TABLE 124. CANADA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY OLIGONUCLEOTIDES, 2018-2030 (USD MILLION)
TABLE 125. CANADA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY PEPTIDES, 2018-2030 (USD MILLION)
TABLE 126. CANADA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY PROTEINS, 2018-2030 (USD MILLION)
TABLE 127. CANADA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY SMALL MOLECULES, 2018-2030 (USD MILLION)
TABLE 128. CANADA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY PRODUCTION SCALE, 2018-2030 (USD MILLION)
TABLE 129. CANADA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY CLINICAL SCALE, 2018-2030 (USD MILLION)
TABLE 130. CANADA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY COMMERCIAL SCALE, 2018-2030 (USD MILLION)
TABLE 131. CANADA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 132. CANADA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY MANUFACTURING TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 133. CANADA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY BIOCATALYSIS, 2018-2030 (USD MILLION)
TABLE 134. CANADA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY FERMENTATION, 2018-2030 (USD MILLION)
TABLE 135. MEXICO ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 136. MEXICO ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY ANALYTICAL SERVICES, 2018-2030 (USD MILLION)
TABLE 137. MEXICO ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY CLINICAL MANUFACTURING, 2018-2030 (USD MILLION)
TABLE 138. MEXICO ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY COMMERCIAL MANUFACTURING, 2018-2030 (USD MILLION)
TABLE 139. MEXICO ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 140. MEXICO ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 141. MEXICO ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY CELL THERAPIES, 2018-2030 (USD MILLION)
TABLE 142. MEXICO ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY GENE THERAPIES, 2018-2030 (USD MILLION)
TABLE 143. MEXICO ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY OLIGONUCLEOTIDES, 2018-2030 (USD MILLION)
TABLE 144. MEXICO ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY PEPTIDES, 2018-2030 (USD MILLION)
TABLE 145. MEXICO ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY PROTEINS, 2018-2030 (USD MILLION)
TABLE 146. MEXICO ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY SMALL MOLECULES, 2018-2030 (USD MILLION)
TABLE 147. MEXICO ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY PRODUCTION SCALE, 2018-2030 (USD MILLION)
TABLE 148. MEXICO ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY CLINICAL SCALE, 2018-2030 (USD MILLION)
TABLE 149. MEXICO ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY COMMERCIAL SCALE, 2018-2030 (USD MILLION)
TABLE 150. MEXICO ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 151. MEXICO ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY MANUFACTURING TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 152. MEXICO ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY BIOCATALYSIS, 2018-2030 (USD MILLION)
TABLE 153. MEXICO ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY FERMENTATION, 2018-2030 (USD MILLION)
TABLE 154. BRAZIL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 155. BRAZIL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY ANALYTICAL SERVICES, 2018-2030 (USD MILLION)
TABLE 156. BRAZIL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY CLINICAL MANUFACTURING, 2018-2030 (USD MILLION)
TABLE 157. BRAZIL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY COMMERCIAL MANUFACTURING, 2018-2030 (USD MILLION)
TABLE 158. BRAZIL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 159. BRAZIL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 160. BRAZIL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY CELL THERAPIES, 2018-2030 (USD MILLION)
TABLE 161. BRAZIL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY GENE THERAPIES, 2018-2030 (USD MILLION)
TABLE 162. BRAZIL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY OLIGONUCLEOTIDES, 2018-2030 (USD MILLION)
TABLE 163. BRAZIL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY PEPTIDES, 2018-2030 (USD MILLION)
TABLE 164. BRAZIL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY PROTEINS, 2018-2030 (USD MILLION)
TABLE 165. BRAZIL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY SMALL MOLECULES, 2018-2030 (USD MILLION)
TABLE 166. BRAZIL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY PRODUCTION SCALE, 2018-2030 (USD MILLION)
TABLE 167. BRAZIL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY CLINICAL SCALE, 2018-2030 (USD MILLION)
TABLE 168. BRAZIL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY COMMERCIAL SCALE, 2018-2030 (USD MILLION)
TABLE 169. BRAZIL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 170. BRAZIL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY MANUFACTURING TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 171. BRAZIL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY BIOCATALYSIS, 2018-2030 (USD MILLION)
TABLE 172. BRAZIL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY FERMENTATION, 2018-2030 (USD MILLION)
TABLE 173. ARGENTINA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 174. ARGENTINA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY ANALYTICAL SERVICES, 2018-2030 (USD MILLION)
TABLE 175. ARGENTINA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY CLINICAL MANUFACTURING, 2018-2030 (USD MILLION)
TABLE 176. ARGENTINA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY COMMERCIAL MANUFACTURING, 2018-2030 (USD MILLION)
TABLE 177. ARGENTINA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 178. ARGENTINA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 179. ARGENTINA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY CELL THERAPIES, 2018-2030 (USD MILLION)
TABLE 180. ARGENTINA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY GENE THERAPIES, 2018-2030 (USD MILLION)
TABLE 181. ARGENTINA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY OLIGONUCLEOTIDES, 2018-2030 (USD MILLION)
TABLE 182. ARGENTINA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY PEPTIDES, 2018-2030 (USD MILLION)
TABLE 183. ARGENTINA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY PROTEINS, 2018-2030 (USD MILLION)
TABLE 184. ARGENTINA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY SMALL MOLECULES, 2018-2030 (USD MILLION)
TABLE 185. ARGENTINA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY PRODUCTION SCALE, 2018-2030 (USD MILLION)
TABLE 186. ARGENTINA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY CLINICAL SCALE, 2018-2030 (USD MILLION)
TABLE 187. ARGENTINA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY COMMERCIAL SCALE, 2018-2030 (USD MILLION)
TABLE 188. ARGENTINA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 189. ARGENTINA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY MANUFACTURING TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 190. ARGENTINA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY BIOCATALYSIS, 2018-2030 (USD MILLION)
TABLE 191. ARGENTINA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY FERMENTATION, 2018-2030 (USD MILLION)
TABLE 192. EUROPE, MIDDLE EAST & AFRICA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 193. EUROPE, MIDDLE EAST & AFRICA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY ANALYTICAL SERVICES, 2018-2030 (USD MILLION)
TABLE 194. EUROPE, MIDDLE EAST & AFRICA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY CLINICAL MANUFACTURING, 2018-2030 (USD MILLION)
TABLE 195. EUROPE, MIDDLE EAST & AFRICA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY COMMERCIAL MANUFACTURING, 2018-2030 (USD MILLION)
TABLE 196. EUROPE, MIDDLE EAST & AFRICA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 197. EUROPE, MIDDLE EAST & AFRICA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 198. EUROPE, MIDDLE EAST & AFRICA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY CELL THERAPIES, 2018-2030 (USD MILLION)
TABLE 199. EUROPE, MIDDLE EAST & AFRICA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY GENE THERAPIES, 2018-2030 (USD MILLION)
TABLE 200. EUROPE, MIDDLE EAST & AFRICA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY OLIGONUCLEOTIDES, 2018-2030 (USD MILLION)
TABLE 201. EUROPE, MIDDLE EAST & AFRICA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY PEPTIDES, 2018-2030 (USD MILLION)
TABLE 202. EUROPE, MIDDLE EAST & AFRICA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY PROTEINS, 2018-2030 (USD MILLION)
TABLE 203. EUROPE, MIDDLE EAST & AFRICA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY SMALL MOLECULES, 2018-2030 (USD MILLION)
TABLE 204. EUROPE, MIDDLE EAST & AFRICA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY PRODUCTION SCALE, 2018-2030 (USD MILLION)
TABLE 205. EUROPE, MIDDLE EAST & AFRICA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY CLINICAL SCALE, 2018-2030 (USD MILLION)
TABLE 206. EUROPE, MIDDLE EAST & AFRICA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY COMMERCIAL SCALE, 2018-2030 (USD MILLION)
TABLE 207. EUROPE, MIDDLE EAST & AFRICA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 208. EUROPE, MIDDLE EAST & AFRICA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY MANUFACTURING TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 209. EUROPE, MIDDLE EAST & AFRICA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY BIOCATALYSIS, 2018-2030 (USD MILLION)
TABLE 210. EUROPE, MIDDLE EAST & AFRICA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY FERMENTATION, 2018-2030 (USD MILLION)
TABLE 211. EUROPE, MIDDLE EAST & AFRICA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 212. UNITED KINGDOM ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 213. UNITED KINGDOM ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY ANALYTICAL SERVICES, 2018-2030 (USD MILLION)
TABLE 214. UNITED KINGDOM ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY CLINICAL MANUFACTURING, 2018-2030 (USD MILLION)
TABLE 215. UNITED KINGDOM ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY COMMERCIAL MANUFACTURING, 2018-2030 (USD MILLION)
TABLE 216. UNITED KINGDOM ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 217. UNITED KINGDOM ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 218. UNITED KINGDOM ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY CELL THERAPIES, 2018-2030 (USD MILLION)
TABLE 219. UNITED KINGDOM ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY GENE THERAPIES, 2018-2030 (USD MILLION)
TABLE 220. UNITED KINGDOM ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY OLIGONUCLEOTIDES, 2018-2030 (USD MILLION)
TABLE 221. UNITED KINGDOM ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY PEPTIDES, 2018-2030 (USD MILLION)
TABLE 222. UNITED KINGDOM ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY PROTEINS, 2018-2030 (USD MILLION)
TABLE 223. UNITED KINGDOM ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY SMALL MOLECULES, 2018-2030 (USD MILLION)
TABLE 224. UNITED KINGDOM ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY PRODUCTION SCALE, 2018-2030 (USD MILLION)
TABLE 225. UNITED KINGDOM ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY CLINICAL SCALE, 2018-2030 (USD MILLION)
TABLE 226. UNITED KINGDOM ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY COMMERCIAL SCALE, 2018-2030 (USD MILLION)
TABLE 227. UNITED KINGDOM ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 228. UNITED KINGDOM ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY MANUFACTURING TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 229. UNITED KINGDOM ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY BIOCATALYSIS, 2018-2030 (USD MILLION)
TABLE 230. UNITED KINGDOM ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY FERMENTATION, 2018-2030 (USD MILLION)
TABLE 231. GERMANY ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 232. GERMANY ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY ANALYTICAL SERVICES, 2018-2030 (USD MILLION)
TABLE 233. GERMANY ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY CLINICAL MANUFACTURING, 2018-2030 (USD MILLION)
TABLE 234. GERMANY ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY COMMERCIAL MANUFACTURING, 2018-2030 (USD MILLION)
TABLE 235. GERMANY ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 236. GERMANY ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 237. GERMANY ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY CELL THERAPIES, 2018-2030 (USD MILLION)
TABLE 238. GERMANY ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY GENE THERAPIES, 2018-2030 (USD MILLION)
TABLE 239. GERMANY ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY OLIGONUCLEOTIDES, 2018-2030 (USD MILLION)
TABLE 240. GERMANY ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY PEPTIDES, 2018-2030 (USD MILLION)
TABLE 241. GERMANY ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY PROTEINS, 2018-2030 (USD MILLION)
TABLE 242. GERMANY ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY SMALL MOLECULES, 2018-2030 (USD MILLION)
TABLE 243. GERMANY ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY PRODUCTION SCALE, 2018-2030 (USD MILLION)
TABLE 244. GERMANY ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY CLINICAL SCALE, 2018-2030 (USD MILLION)
TABLE 245. GERMANY ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY COMMERCIAL SCALE, 2018-2030 (USD MILLION)
TABLE 246. GERMANY ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 247. GERMANY ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY MANUFACTURING TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 248. GERMANY ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY BIOCATALYSIS, 2018-2030 (USD MILLION)
TABLE 249. GERMANY ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY FERMENTATION, 2018-2030 (USD MILLION)
TABLE 250. FRANCE ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 251. FRANCE ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY ANALYTICAL SERVICES, 2018-2030 (USD MILLION)
TABLE 252. FRANCE ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY CLINICAL MANUFACTURING, 2018-2030 (USD MILLION)
TABLE 253. FRANCE ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY COMMERCIAL MANUFACTURING, 2018-2030 (USD MILLION)
TABLE 254. FRANCE ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 255. FRANCE ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 256. FRANCE ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY CELL THERAPIES, 2018-2030 (USD MILLION)
TABLE 257. FRANCE ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY GENE THERAPIES, 2018-2030 (USD MILLION)
TABLE 258. FRANCE ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY OLIGONUCLEOTIDES, 2018-2030 (USD MILLION)
TABLE 259. FRANCE ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY PEPTIDES, 2018-2030 (USD MILLION)
TABLE 260. FRANCE ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY PROTEINS, 2018-2030 (USD MILLION)
TABLE 261. FRANCE ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY SMALL MOLECULES, 2018-2030 (USD MILLION)
TABLE 262. FRANCE ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY PRODUCTION SCALE, 2018-2030 (USD MILLION)
TABLE 263. FRANCE ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY CLINICAL SCALE, 2018-2030 (USD MILLION)
TABLE 264. FRANCE ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY COMMERCIAL SCALE, 2018-2030 (USD MILLION)
TABLE 265. FRANCE ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 266. FRANCE ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY MANUFACTURING TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 267. FRANCE ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY BIOCATALYSIS, 2018-2030 (USD MILLION)
TABLE 268. FRANCE ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY FERMENTATION, 2018-2030 (USD MILLION)
TABLE 269. RUSSIA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 270. RUSSIA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY ANALYTICAL SERVICES, 2018-2030 (USD MILLION)
TABLE 271. RUSSIA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY CLINICAL MANUFACTURING, 2018-2030 (USD MILLION)
TABLE 272. RUSSIA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY COMMERCIAL MANUFACTURING, 2018-2030 (USD MILLION)
TABLE 273. RUSSIA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 274. RUSSIA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 275. RUSSIA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY CELL THERAPIES, 2018-2030 (USD MILLION)
TABLE 276. RUSSIA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY GENE THERAPIES, 2018-2030 (USD MILLION)
TABLE 277. RUSSIA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY OLIGONUCLEOTIDES, 2018-2

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Active Pharmaceutical Ingredients CDMO market report include:
  • Lonza Group Ltd
  • Thermo Fisher Scientific Inc
  • Catalent Inc
  • Evonik Industries AG
  • WuXi AppTec Co., Ltd
  • Siegfried Holding AG
  • Divi’s Laboratories Ltd
  • Jubilant Life Sciences Ltd
  • Piramal Enterprises Ltd
  • Granules India Ltd

Table Information

Report AttributeDetails
No. of Pages181
PublishedMay 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 140.01 Billion
Forecasted Market Value ( USD ) by 2030 $ 229.63 Billion
Compound Annual Growth Rate10.4%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Active Pharmaceutical Ingredients Market by Therapeutic Application, Molecule Type, Source, Route Of Administration, Application, Product Category - Global Forecast to 2030 - Product Image

Active Pharmaceutical Ingredients Market by Therapeutic Application, Molecule Type, Source, Route Of Administration, Application, Product Category - Global Forecast to 2030

  • Report
  • 185 Pages
  • Global
From
Small Molecule CDMO - Global Strategic Business Report - Product Image

Small Molecule CDMO - Global Strategic Business Report

  • Report
  • 72 Pages
  • Global
From
Peptide and Oligonucleotide CDMO - Global Strategic Business Report - Product Image

Peptide and Oligonucleotide CDMO - Global Strategic Business Report

  • Report
  • 370 Pages
  • Global
From
Small Molecule Innovator CDMO Market Report 2025 - Product Image

Small Molecule Innovator CDMO Market Report 2025

  • Report
  • 200 Pages
  • Global
From
Semi-Solid CDMO Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2019-2029F - Product Image

Semi-Solid CDMO Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2019-2029F

  • Report
  • 185 Pages
  • Global
From

About the Active Pharmaceutical Ingredients CDMO Market

The Active Pharmaceutical Ingredients (API) CDMO market is a subset of the pharmaceutical manufacturing industry. It involves the production of APIs, which are the active ingredients in drugs that are responsible for their therapeutic effects. CDMOs provide a range of services, from drug development and manufacturing to packaging and distribution. They are often used by pharmaceutical companies to outsource the production of APIs, allowing them to focus on other aspects of drug development. CDMOs are typically specialized in specific areas of drug production, such as synthesis, formulation, and analytical testing. They are also responsible for ensuring that the APIs they produce meet the necessary regulatory standards. Some of the major players in the API CDMO market include Lonza, Patheon, Boehringer Ingelheim, Cambrex, and Evonik. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.